TLDR: Alphabet’s subsidiary, Isomorphic Labs, has entered into strategic research collaboration agreements with Novartis AG and Eli Lilly & Co. Under the partnership with Lilly, Isomorphic Labs will receive an upfront cash payment of $45 million and is eligible for performance-based milestone payments of up to $1.7 billion. Isomorphic Labs also agreed to discover small molecule therapeutics against three undisclosed targets with Novartis and will receive an upfront payment of $37.5 million, along with potential milestone payments of up to $1.2 billion. The collaborations aim to leverage AI-driven drug discovery to unlock new possibilities in the pharmaceutical industry.
